Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Controlled Trial of Rivaroxaban for the Prevention of Major Cardiovascular Events in Patients With Coronary or Peripheral Artery Disease (COMPASS - Cardiovascular OutcoMes for People Using Anticoagulation StrategieS).
Brief Summary: The primary objectives of this study are:

* To determine whether rivaroxaban 2.5 mg twice daily (bid) + aspirin 100 mg once daily (od) compared with aspirin 100 mg od reduces the risk of a composite of myocardial infarction, stroke, or cardiovascular death in subjects with coronary artery disease (CAD) or peripheral artery disease (PAD);
* To determine whether rivaroxaban 5 mg bid compared with aspirin 100 mg od reduces the risk of a composite of myocardial infarction, stroke or cardiovascular death in subjects with CAD or PAD.


Options:
A: Arm Label: Isosorbide Mononitrate XL (ISMN); Type: ACTIVE_COMPARATOR; Interventions: Drug: Isosorbide Mononitrate XL (ISMN) | Arm Label: Cilostazol; Type: ACTIVE_COMPARATOR; Interventions: Drug: Cilostazol | Arm Label: ISMN XL and Cilostazol; Type: ACTIVE_COMPARATOR; Interventions: Drug: ISMN XL and Cilostazol | Arm Label: Neither ISMN nor cilostazol; Type: PLACEBO_COMPARATOR; Interventions: Other: Neither ISMN nor cilostazol | Intervention Type: DRUG; Name: Isosorbide Mononitrate XL (ISMN); Assigned to Arm(s): Isosorbide Mononitrate XL (ISMN) | Intervention Type: DRUG; Name: Cilostazol; Assigned to Arm(s): Cilostazol | Intervention Type: DRUG; Name: ISMN XL and Cilostazol; Assigned to Arm(s): ISMN XL and Cilostazol | Intervention Type: OTHER; Name: Neither ISMN nor cilostazol; Assigned to Arm(s): Neither ISMN nor cilostazol
B: Arm Label: Dabigatran Etexilate; Type: EXPERIMENTAL; Interventions: Drug: Dabigatran Etexilate | Arm Label: Warfarin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Warfarin | Intervention Type: DRUG; Name: Dabigatran Etexilate; Assigned to Arm(s): Dabigatran Etexilate | Intervention Type: DRUG; Name: Warfarin; Assigned to Arm(s): Warfarin
C: Arm Label: Rivaroxaban 2.5mg + Aspirin 100mg; Type: EXPERIMENTAL; Interventions: Drug: Rivaroxaban (Xarelto, BAY59-7939), Drug: Aspirin, Drug: Pantoprazole, Drug: Pantoprazole placebo | Arm Label: Rivaroxaban 5mg + Aspirin Placebo; Type: EXPERIMENTAL; Interventions: Drug: Rivaroxaban (Xarelto, BAY59-7939), Drug: Aspirin placebo, Drug: Pantoprazole, Drug: Pantoprazole placebo | Arm Label: Rivaroxaban Placebo + Aspirin 100mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Aspirin, Drug: Rivaroxaban placebo, Drug: Pantoprazole, Drug: Pantoprazole placebo | Intervention Type: DRUG; Name: Rivaroxaban (Xarelto, BAY59-7939); Assigned to Arm(s): Rivaroxaban 2.5mg + Aspirin 100mg | Intervention Type: DRUG; Name: Rivaroxaban (Xarelto, BAY59-7939); Assigned to Arm(s): Rivaroxaban 5mg + Aspirin Placebo | Intervention Type: DRUG; Name: Aspirin; Assigned to Arm(s): Rivaroxaban 2.5mg + Aspirin 100mg, Rivaroxaban Placebo + Aspirin 100mg | Intervention Type: DRUG; Name: Aspirin placebo; Assigned to Arm(s): Rivaroxaban 5mg + Aspirin Placebo | Intervention Type: DRUG; Name: Rivaroxaban placebo; Assigned to Arm(s): Rivaroxaban Placebo + Aspirin 100mg | Intervention Type: DRUG; Name: Pantoprazole; Assigned to Arm(s): Rivaroxaban 2.5mg + Aspirin 100mg, Rivaroxaban 5mg + Aspirin Placebo, Rivaroxaban Placebo + Aspirin 100mg | Intervention Type: DRUG; Name: Pantoprazole placebo; Assigned to Arm(s): Rivaroxaban 2.5mg + Aspirin 100mg, Rivaroxaban 5mg + Aspirin Placebo, Rivaroxaban Placebo + Aspirin 100mg
D: Arm Label: Combination Clopidogrel and asprin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Clopidogrel | Arm Label: Asprin and placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo of clopidogrel and Asprin | Intervention Type: DRUG; Name: Clopidogrel; Assigned to Arm(s): Combination Clopidogrel and asprin | Intervention Type: DRUG; Name: Placebo of clopidogrel and Asprin; Assigned to Arm(s): Asprin and placebo

Answer: C